HRR Testing & PARPi Underutilized in Patients With Metastatic Prostate Cancer
Only half of patients with metastatic castration-resistant prostate cancer were tested for HRR mutations, and PARP inhibitors were underused.
Apr 11, 2024
Search
Advertisement
CONDITION SPOTLIGHT
Condition Spotlight: Prostate Cancer
A collection of feature articles, study abstracts, and other resources all focused on prostate cancer.
Baseline Bone Pain Associated With Worse Survival in Metastatic Prostate Cancer
Baseline Bone Pain Associated With Worse Survival in Metastatic Prostate Cancer
Men with metastatic hormone-sensitive prostate cancer who experience baseline bone pain have worse survival outcomes despite treatment intensification.
Racial Disparities in Healthcare Perception Among Patients With Prostate Cancer
Racial Disparities in Healthcare Perception Among Patients With Prostate Cancer
Various sessions at the 2024 ASCO Genitourinary Cancers Symposium reviewed health care discrimination and disparities among patients with prostate cancer.
Advertisement
PW QUIZ
Advertisement
Bone-Protective Agents Beneficial in Patients Receiving Radium-223 for Metastatic Prostate Cancer
Bone-Protective Agents Beneficial in Patients Receiving Radium-223 for Metastatic Prostate Cancer
Researchers emphasized the importance of bone-protective agents in patients treated for metastatic castration-resistant prostate cancer.
Predicting Survival in Newly Diagnosed Metastatic Prostate Cancer: The Value of PSMA PET Imaging & AI
Predicting Survival in Newly Diagnosed Metastatic Prostate Cancer: The Value of PSMA PET Imaging & AI
Researchers found correlations between PSMA PET total tumor burden and survival in patients with high-volume metastatic hormone-sensitive prostate cancer.
Think You Know the Latest in Prostate Cancer Research?
Think You Know the Latest in Prostate Cancer Research?
Test your knowledge of the latest prostate cancer studies and news—take this quiz!
RECIP 1.0’s Prognostic Value in Biochemically Recurrent Prostate Cancer Imaging
RECIP 1.0’s Prognostic Value in Biochemically Recurrent Prostate Cancer Imaging
The following is a summary of "Prognostic utility of RECIP 1.0 with manual and AI-based...
EXPLORE MORE
Mortality Risk Comparable With Continuous Versus Intermittent ADT for Prostate Cancer
An analysis of 12 clinical trials shows no difference in mortality risk with continuous versus intermittent androgen deprivation therapy for prostate cancer.
In Clinical Trial Setting, Survival Is Similar for Black & White Patients With Prostate Cancer
Both Black and White patients with metastatic castration-sensitive prostate cancer (mCSPC) showed similar progression-free survival and overall survival in a clinical trial setting.
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
